| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Laura Brege is Director at PCRX and has filed Form 4s across 3 companies. Laura Brege's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.9M at current prices.
Historically, Laura Brege's trades have earned a middling insider score of 58/100 across 7 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +16.1%.
The biggest single holding is MIRM (~$1.4M) as Director. The MIRM filings lean toward selling, a net 7,000 shares.
Laura Brege has 59 Form 4 filings on record from February 2015 to June 2026, across 5 companies: Director at Mirum Pharmaceuticals (MIRM), 2019–2026; Director at Pacira BioSciences (PCRX), 2015–2026; Director at Edgewise Therapeutics (EWTX), 2022–2026, and 2 more.
The 98 reported transactions were 54 option or other derivative awards, 16 option exercises, 14 open-market sales and 12 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $125K and 13 sales worth about $4.9M.
The largest open-market purchase was 10,000 shares of MIRM at an average $11.22 on September 10, 2019, about $112K.
The largest open-market sale was 17,000 shares of MIRM at an average $74.40 on September 11, 2025, about $1.3M. Twelve months later MIRM was up 29%.
3 of the 5 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 2 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Director | Sale+OE | 17,000 | $74.40 | $1,264,868.43 | -52.0% | -14.9% | +29.3% | |
| Jun 4, 2025 | ACAD Acadia Pharmaceuticals Inc | Director | Sell | 14,446 | $21.78 | $314,633.88 | -48.9% | +18.0% | - | |
| Aug 16, 2024 | PCRX Pacira Biosciences, Inc. | Director | Buy | 1,000 | $12.81 | $12,810.00 | +6.0% | +26.5% | +91.5% | |
| Jun 12, 2023 | ACAD Acadia Pharmaceuticals Inc | Director | Sell10b5-1 | 4,500 | $24.87 | $111,906.00 | -25.0% | +10.2% | -38.9% | |
| Jun 5, 2023 | PCRX Pacira Biosciences, Inc. | Director | Sell10b5-1 | 600 | $38.74 | $23,244.00 | -5.9% | -9.8% | -20.8% | |
| Apr 3, 2023 | PCRX Pacira Biosciences, Inc. | Director | Sale+OE10b5-1 | 7,000 | $40.72 | $285,040.00 | -40.8% | -3.1% | -31.1% | |
| Jan 12, 2023 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 12,500 | $18.25 | $228,125.00 | - | 0.0% | +56.7% | |
| Nov 16, 2020 | PCRX Pacira Biosciences, Inc. | Director | Sale+OE | 12,000 | $65.95 | $791,400.00 | -60.2% | - | - | |
| Jun 5, 2020 | PCRX Pacira Biosciences, Inc. | Director | Sell | 2,100 | $48.70 | $102,270.00 | -24.0% | - | - | |
| Jan 7, 2020 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 10,000 | $42.19 | $421,900.00 | - | - | - |